Barinthus Biotherapeutics (BRNS) EBIT Margin (2020 - 2024)
Barinthus Biotherapeutics (BRNS) reported EBIT Margin of 62.66% for Q3 2024, up 99.21% quarter-over-quarter from 7885.33% in Q2 2023.
Barinthus Biotherapeutics (BRNS) EBIT Margin (2020 - 2024) Analysis & Trends
Barinthus Biotherapeutics has reported EBIT Margin for 5 years, with the latest figure at 62.66% in Q3 2024.
- For the quarter ending Q3 2024, EBIT Margin changed N/A year-over-year to 62.66%; the trailing twelve-month figure through Dec 2025 stood at 471.34% (down 1727.0% YoY), and the FY2024 full-year result was 454.07%, up 1000902.0% from the prior year.
- EBIT Margin for Q3 2024 stood at 62.66%, up from 7885.33% in the prior quarter.
- The five-year high for EBIT Margin was 1666800.0% in Q4 2021, with the low at 48128.57% in Q2 2021.
- Historically, EBIT Margin has averaged 104644.19% across 5 years, with a median of 659.43% in 2020.
- Annual changes were most pronounced in 2021 — EBIT Margin surged 166952119 bps — and 2022, when it tumbled 166718862 bps.
- Barinthus Biotherapeutics' EBIT Margin stood at 2721.19% in 2020, then soared by 61353 bps to 1666800.0% in 2021, then plunged by 100 bps to 388.62% in 2022, then tumbled by 1929 bps to 7885.33% in 2023, then surged by 99 bps to 62.66% in 2024.
- The last three EBIT Margin figures came in at 62.66% (Q3 2024), 7885.33% (Q2 2023), and 4590.6% (Q1 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -62.66% |
| Jun 30, 2023 | -7,885.33% |
| Mar 31, 2023 | -4,590.60% |
| Dec 31, 2022 | -388.62% |
| Sep 30, 2022 | 117.37% |
| Jun 30, 2022 | 77.57% |
| Mar 31, 2022 | 4.35% |
| Dec 31, 2021 | 1,666,800.00% |
| Sep 30, 2021 | -29,136.84% |
| Jun 30, 2021 | -48,128.57% |
| Mar 31, 2021 | -2,870.70% |
| Dec 31, 2020 | -2,721.19% |
| Sep 30, 2020 | -43.92% |
| Jun 30, 2020 | -848.53% |
| Mar 31, 2020 | -659.43% |